Jpmorgan Chase & CO Immuneering Corp Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Immuneering Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,974 shares of IMRX stock, worth $12,100. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,974
Previous 1,974
-0.0%
Holding current value
$12,100
Previous $4,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding IMRX
# of Institutions
40Shares Held
3.78MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA1.06MShares$6.48 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0574KShares$3.52 Million0.0% of portfolio
-
Black Rock Inc. New York, NY533KShares$3.27 Million0.0% of portfolio
-
Southport Management, L.L.C. Wilson, WY245KShares$1.5 Million4.03% of portfolio
-
Geode Capital Management, LLC Boston, MA230KShares$1.41 Million0.0% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $162M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...